- Investing Ideas
- /
- U.S. Pharmaceuticals & Biotech High Growth Potential Companies
U.S. Pharmaceuticals & Biotech High Growth Potential Companies
UPDATED Apr 21, 2024
Companies with a Future performance score of at least 3, ordered by Future performance score.
166 companies
| Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | ||
|---|---|---|---|---|---|---|---|---|---|---|
SCPH | US$4.56 | -6.2% | -55.1% | US$164.4m | US$19.50 | PS12.1x | E59.8% | n/a | ||
LEGN | US$46.19 | -10.7% | -32.1% | US$8.4b | US$86.33 | PS29.5x | E61.0% | n/a | ||
GERN | US$3.69 | 7.0% | 39.2% | US$2.2b | US$5.08 | PS9168.5x | E62.1% | n/a | ||
ATNM | US$6.85 | -18.8% | -27.1% | US$201.4m | US$25.47 | PS2486x | E63.2% | n/a | ||
VRNA | US$15.72 | -0.5% | -31.7% | US$1.3b | US$33.86 | PB5.1x | E58.6% | n/a | ||
ALVO | US$13.22 | 5.8% | 47.1% | US$3.7b | US$16.50 | PS39.6x | E95.2% | n/a | ||
MEDP | US$372.00 | -3.9% | 98.7% | US$11.5b | US$402.04 | PE40.8x | E14.7% | n/a | ||
OLK | US$21.87 | -3.8% | 1.1% | US$2.7b | US$26.00 | PS16x | E61.0% | n/a | ||
PCRX | US$26.25 | -1.1% | -42.7% | US$1.2b | US$45.73 | PE29.1x | E29.3% | n/a | ||
IPA | US$1.26 | 1.6% | -58.6% | US$33.2m | US$7.00 | PS1.9x | E61.2% | n/a | ||
AMPH | US$40.01 | -1.9% | -2.2% | US$2.0b | US$62.60 | PE14.2x | E19.7% | n/a | ||
CDXC | US$3.69 | -6.1% | 169.3% | US$278.5m | US$6.08 | PS3.3x | E93.2% | n/a | ||
CTKB | US$5.92 | -1.7% | -41.7% | US$774.5m | US$10.00 | PS4x | E92.1% | n/a | ||
TLRY | US$1.73 | -2.8% | -26.4% | US$1.3b | US$2.37 | PS1.8x | E86.1% | n/a | ||
BLFS | US$15.86 | 1.1% | -18.0% | US$718.5m | US$23.13 | PS5x | E60.7% | n/a | ||
CDMO | US$6.39 | -6.0% | -67.1% | US$404.1m | US$12.25 | PS2.9x | E86.4% | n/a | ||
ADMA | US$6.27 | 4.8% | 82.3% | US$1.5b | US$8.38 | PS5.6x | E32.5% | n/a | ||
EXEL | US$22.52 | -0.8% | 19.8% | US$6.6b | US$26.63 | PE32x | E22.6% | n/a | ||
CORT | US$22.95 | -0.9% | 2.0% | US$2.4b | US$42.80 | PE22.6x | E25.9% | n/a | ||
ICPT | US$19.00 | 0.1% | 19.1% | US$794.7m | US$19.00 | PS2.5x | E42.4% | n/a | ||
ABBV | US$166.41 | 2.9% | 1.4% | US$294.7b | US$184.14 | PE61.1x | E23.4% | 3.7% | ||
EXAS | US$60.96 | -6.7% | -7.9% | US$11.1b | US$89.27 | PS4.4x | E61.9% | n/a | ||
MRK | US$125.78 | -0.3% | 8.5% | US$318.6b | US$137.58 | PE872.9x | E25.9% | 2.4% | ||
HRTX | US$2.64 | -10.5% | -0.8% | US$397.0m | US$7.00 | PS3.1x | E68.5% | n/a |